Today's 10Q also included information about the gr
Post# of 72440
Quote:
The Company is collaborating with a Regional Biocontainment Laboratory (RBL) for federal grants to fund continued research on Brilacidin as a treatment for
SARSCoV2. An earlier grant application was unsuccessful. At the time of that grant filing deadline, the only research data available was limited to nonhuman
Vero cells. Subsequent to the filing, human cell line experiments were completed and the data is now available. Additional grant applications incorporating the
new data are planned for submission before the end of 2020.